| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 09/12/2002 | US20020128240 Treatment of hyperproliferative diseases using active vitamin D analogues |
| 09/12/2002 | US20020128173 Method of treating or preventing migraine headaches |
| 09/12/2002 | US20020128171 Administering to the mammal a therapeutically effective amount of a compound that increases nitric oxide (NO) activity as measured in a standard gastric emptying assay |
| 09/12/2002 | US20020127694 2786, a novel human aminopeptidase |
| 09/12/2002 | US20020127676 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 09/12/2002 | US20020127668 Polypeptide for use in the diagnosis and treatment of cancer, nervous system and vessicular transport disorders |
| 09/12/2002 | US20020127627 Measuring diacylglycerol acetyltransferase activity; obtain enzmatic substrate, expose to microsomes, terminate reaction, monitor triglyceride generation |
| 09/12/2002 | US20020127221 Urocortin proteins and uses thereof |
| 09/12/2002 | US20020127213 Administering to patient a therapeutically effective amount of both an N-alkyl derivative of deoxynojirimycin and a glucocerebrosidase enzyme to alleviate or inhibit glycolipid storage disease; Gaucher's disease |
| 09/12/2002 | US20020127211 Increasing or facilitating absorption of minerals from diet using enteral nutritional composition which includes lactobacilli |
| 09/12/2002 | DE10111877A1 Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate New imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them |
| 09/12/2002 | DE10110747A1 Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use |
| 09/12/2002 | CA2440642A1 Dimeric isoflavones |
| 09/12/2002 | CA2440161A1 Inhibitor of monoamine uptake |
| 09/12/2002 | CA2440038A1 Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof |
| 09/12/2002 | CA2439941A1 Secreted proteins |
| 09/12/2002 | CA2439934A1 Use of protein histidine phosphatase |
| 09/12/2002 | CA2439929A1 Modified protamine with reduced immunogenicity |
| 09/12/2002 | CA2439854A1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes |
| 09/12/2002 | CA2439849A1 Antagonists of mcp-1 function and methods of use thereof |
| 09/12/2002 | CA2439793A1 Composition for the treatment of diabetes mellitus |
| 09/12/2002 | CA2439779A1 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna |
| 09/12/2002 | CA2439687A1 Use of certain steroids for treatment of blood cell deficiencies |
| 09/12/2002 | CA2439682A1 Modified ciliary neurotrophic factor (cntf) with reduced immunogenicity |
| 09/12/2002 | CA2439594A1 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 09/12/2002 | CA2439574A1 Catecholate beta-lactam conjugates, method for producing the same and the use thereof |
| 09/12/2002 | CA2439293A1 Enteral formulation |
| 09/12/2002 | CA2439205A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439203A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439200A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439197A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439196A1 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | CA2439195A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439192A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2438815A1 Novel 2,5-diazabicyclo[2.2.1]heptane derivatives |
| 09/12/2002 | CA2437594A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | CA2340556A1 Use of zinc tranexamate in the treatment of diabetes |
| 09/11/2002 | EP1239050A1 Method of testing remedy or preventive for hyperlipemia |
| 09/11/2002 | EP1239034A2 Large circular target-specific antisense nucleic acids |
| 09/11/2002 | EP1238973A1 Novel substituted tricyclic compounds |
| 09/11/2002 | EP1238667A2 Use of benzothiophenes for treatment of hypercholesterolaemia |
| 09/11/2002 | EP1238082A2 Ifn-alpha homologues |
| 09/11/2002 | EP1238077A1 Tnfr/opg-like molecules and uses thereof |
| 09/11/2002 | EP1237919A1 Interferon-alpha induced gene |
| 09/11/2002 | EP1237914A1 Methods for improving secondary metabolite production in fungi |
| 09/11/2002 | EP1237902A1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 09/11/2002 | EP1237898A2 N?6 heterocyclic 8-modified adenosine derivatives |
| 09/11/2002 | EP1237891A1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 09/11/2002 | EP1237890A1 Synthesis and methods of use of 9-substituted guanine derivatives |
| 09/11/2002 | EP1237888A2 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 09/11/2002 | EP1237886A1 Heterocyclic derivatives |
| 09/11/2002 | EP1237880A2 Pyrazine based inhibitors of glycogen synthase kinase 3 |
| 09/11/2002 | EP1237875A1 Substituted imidazole neuropeptide y y5 receptor antagonists |
| 09/11/2002 | EP1237874A2 Selective neurokinin antagonists |
| 09/11/2002 | EP1237864A1 Process for the preparation of amorphous atorvastatin |
| 09/11/2002 | EP1237859A2 Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia |
| 09/11/2002 | EP1237857A1 New phenalkyloxy-phenyl derivatives |
| 09/11/2002 | EP1237856A1 New tri-substituted phenyl derivatives and analogues |
| 09/11/2002 | EP1237855A1 Crystalline form of (s)-2 ethoxy-3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid |
| 09/11/2002 | EP1237854A1 Comminuted form of (s)-2-ethoxy -3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid |
| 09/11/2002 | EP1237580A2 Amphiphilic polymers and polypeptide conjugates comprising same |
| 09/11/2002 | EP1237578A2 Micro-cluster liquids and methods of making and using them |
| 09/11/2002 | EP1237575A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 09/11/2002 | EP1237563A1 Nutritional composition, methods of producing said composition and methods of using said composition |
| 09/11/2002 | EP1237553A2 The combination of a serotonin reuptake inhibitor and a 5-ht 2c? antagonist, inverse agonist or partial agonist |
| 09/11/2002 | EP1237547A2 Compounds for inhibiting diseases and preparing cells for transplantation |
| 09/11/2002 | EP1073444A4 A food composition and method of using same |
| 09/11/2002 | EP0910399B1 Stable pharmaceutical composition of bdnf |
| 09/11/2002 | EP0813529B1 Arginine analogues having nitric oxide synthase inhibitor activity |
| 09/11/2002 | EP0763036B1 [a]-ANNELATED PYRROLE DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
| 09/11/2002 | EP0759776B1 Use of igf-i or analogues thereof in the prevention of diabetes |
| 09/11/2002 | CN1368975A Organosilyl compounds having nuclear hormone receptor modulating activity |
| 09/11/2002 | CN1368970A Substituted 1,4-dihydroindeno [1,2-C] pyrazoles as inhibitors of tyrosine kinase |
| 09/11/2002 | CN1368963A Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 09/11/2002 | CN1368961A Compounds for modulation of PPAP gamma activity |
| 09/11/2002 | CN1368960A Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 09/11/2002 | CN1368948A Crystals of sodium salt of pravastatin |
| 09/11/2002 | CN1368892A Sustained release formulation of peptide |
| 09/11/2002 | CN1368885A Compositions and methods for identifying antigens which elicit an immune response |
| 09/11/2002 | CN1368884A Method for modulating FXR receptor activity |
| 09/11/2002 | CN1368883A Method for reducing serum glucose and trigluceride and inhibiting vascular formation by indolealkanoic acids |
| 09/11/2002 | CN1368881A Use of inhibitors of renin-angiotensin systemin prevention of cardiovascular events |
| 09/11/2002 | CN1368879A Use of (-)(3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance type 2 diabetes, hyperlipidemia and hyperuricemia |
| 09/11/2002 | CN1368853A Prophylactic dietary supplement based on milk |
| 09/11/2002 | CN1368374A Medicine for treating diabetes and its preparing process |
| 09/11/2002 | CN1368316A Nano medicine 'Shuxinjangzhi' and its preparing process |
| 09/11/2002 | CN1368251A Nano medicine 'Changchunbao' and its preparing process |
| 09/11/2002 | CN1368180A Nano fleece flower root medicine and its preparing process |
| 09/11/2002 | CN1368133A Nano medicine for treating laugh inability and its preparing process |
| 09/11/2002 | CN1368078A Nano medicine 'Qingshengjianfei' and its preparing process |
| 09/11/2002 | CN1368074A Nano medicine 'Tongmai Jiangzhi' and its preparing process |
| 09/11/2002 | CN1368061A Nano meidcine 'Xiaoshuan Tongluo' and its preparing process |
| 09/11/2002 | CN1368054A Process for preparing soft body of pearl shell as Chinese-medicinal material |
| 09/11/2002 | CN1090631C Heterocyclic compounds, preparation process thereof and medicinal composition containing same |
| 09/11/2002 | CN1090630C Preparation of [1S-[1a, 2b, 3b, 4a(S*)]]-4-[7-[1-(3-chloro-2-thienyl)methyl]propyl]amino]-3H-imidazo [4,5-b] pyridin-3-yl]-N-ethyl-2,3-dyhydroxy pentamethylene formamide |
| 09/11/2002 | CN1090629C Novel Heterocyclic compounds |
| 09/11/2002 | CN1090628C New N-aryl piperidine compounds, process for their preparation and pharmaceutical compositions containing them |
| 09/11/2002 | CN1090627C 2-amino-1,2-indene compounds, process for their preparation and pharmaceutical compositions containing them |
| 09/11/2002 | CN1090491C Oxygen-making up and stamina-strenthening liquid |
| 09/11/2002 | CN1090488C Pharmaceutical for treating diabetes, and its prepe process |